Clinical Trials Logo
  1. Home
  2. Breast Cancer
  3. NCT02517554
  4. Details
NCT02517554 Clinical Trial

A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services

Breast Cancer Clinical Trial

Official title:
A Randomized Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02517554
Other study ID # UPCC 09115
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 2015
Est. completion date November 2019

Study information
Verified date January 2024
Source Abramson Cancer Center at Penn Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this research is to evaluate the relative advantage of remote counseling over usual care in community health practices without access to genetic services. We will evaluate ability of remote telemedicine, referred to going forward as TeleGenetic services (phone or videoconferencing), to increase uptake of genetic testing and identification of genetic carriers compared to usual care. Secondly, we will evaluate the advantages of videoconferencing over telephone for delivery of remote genetic services and the short-term and longitudinal outcomes of TeleGenetic services in socio-demographically diverse patients in community practices.

Recruitment information / eligibility
Status Completed
Enrollment 120
Est. completion date November 2019
Est. primary completion date March 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Eligible participants will include adult men and women (aged 18 and older) who can understand and communicate in English 2. meet National Comprehensive Cancer Network® criteria for cancer genetic testing for breast, ovarian or colorectal cancers 3. have insurance coverage for genetic testing. Exclusion Criteria: 1. Under 18 years old - professional guidelines do not recommend genetic testing for cancer risk in minors. 2. Does not speak English. 3. Does not have insurance.

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site
Baseline and follow up survey
• Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site
Baseline and follow up surveys
• Patient receives written information on how to find genetic services in their area
Baseline and follow up surveys

Locations
Country Name City State
United States Cape Regional Medical Center Cape May Court House New Jersey
United States Union Hospital Elkton Maryland
United States Gettysburg Cancer Center Gettysburg Pennsylvania
United States Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania
United States Drexel Cancer Care at Hahnemann Philadelphia Pennsylvania
United States Kennedy Health Sewell New Jersey
United States Shore Cancer Center Somers Point New Jersey

Sponsors (1)
Lead Sponsor Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Completion of Surveys 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2